Vedolizumab
Biologics
Vedolizumab improves clinical outcomes, induces mucosal healing in UC, chronic pouchitis
Vedolizumab not only induced endoscopic improvements in patients with chronic pouchitis, but also appeared to improve clinical outcomes at week 34, especially in those who achieved mucosal healing at week 14, research showed.
VIDEO: Consensus conference seeks ‘standardization’ of care in pregnant women with IBD
In this video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, spoke with Healio about a consensus conference on the management of IBD in pregnancy.
Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease
The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe Crohn’s disease following induction therapy via IV administration of the biologic.
VIDEO: Multimodal care, ‘aggressive’ medical treatment a must for perianal Crohn’s disease
In this Healio video exclusive, Miguel Regueiro, MD, shares highlights from his presentation at the GUILD Conference, where he discussed the importance of early, multimodal intervention in perianal fistulizing Crohn’s disease.
Triple combination therapy ‘superior to monotherapy,’ improves remission in Crohn’s
A combination of vedolizumab, adalimumab and methotrexate resulted in endoscopic remission at week 26 in more than a third of patients with Crohn’s disease, according to data in Clinical Gastroenterology and Hepatology.
FDA approves subcutaneous Entyvio as maintenance therapy for ulcerative colitis
The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe ulcerative colitis following induction therapy via IV administration of the biologic.
Concomitant 5-ASA treatment does not affect efficacy, safety of vedolizumab in IBD
Concomitant use of 5-aminosalicylic acid did not affect the overall safety and efficacy of IV or subcutaneous vedolizumab in patients with inflammatory bowel disease, according to a post hoc analysis in the Journal of Crohn’s and Colitis.
Vedolizumab, ustekinumab induce similar rates of clinical response, remission in Crohn’s
CHICAGO — Biologic-naive patients treated with vedolizumab and ustekinumab for Crohn’s disease had similar rates of clinical response and remission, although mucosal healing and biologic treatment persistence differed at 36 months.
Vedolizumab induces remission in more than 30% of UC patients with chronic pouchitis
Vedolizumab more effectively induced remission compared with placebo in patients with chronic pouchitis following ileal pouch-anal anastomosis for ulcerative colitis, according to research in The New England Journal of Medicine.